Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
Pfizer(PFE) stock is priced at $27.07, giving the company a market capitalization of 153.93B. It carries a P/E multiple of 19.74 and pays a dividend yield of 6.4%.
As of 2026-03-24, Pfizer(PFE) stock has fluctuated between $26.44 and $27.13. The current price stands at $27.07, placing the stock +2.4% above today's low and -0.2% off the high.
Pfizer(PFE) shares are trading with a volume of 22.18M, against a daily average of 45M.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.
PFE News
Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme di...
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial By Joel South Published Mar 24, 10:52AM EDT Quick Read Pfizer (PFE...
Guggenheim raised the firm’s price target on Pfizer (PFE) to $36 from $35 and keeps a Buy rating on the shares. Topline data for Pfizer’s MEVPRO-1 Phase 3 trial...
Analyst ratings
55%
of 29 ratingsMore PFE News
Key Points Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer inves...
Wondering whether Pfizer at a last close of US$26.97 is genuinely offering value or just looks cheap on the surface? This article breaks down what the current p...
A nurse preparing refrigerated doses of Lyme disease vaccine at a clinical research center. Gary M. Baranec/Associated Press An experimental Lyme disease vacci...
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis....
A tick (Ixodida) - carrier for several diseases of humans and animals, for exampel the dangerous Lyme disease, babesiosis, anaplasmosis, Powassan virus disease...
Shares in French specialty vaccine developer Valneva (VALN) plunged over 38% early Monday despite reporting “clinically meaningful efficacy” results from its mi...
(RTTNews) - Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its inv...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.